Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

4D Molecular Therapeutics, Inc. - Common Stock (NQ:FDMT)

4.150 -0.220 (-5.03%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 17, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about 4D Molecular Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 Next >
Forecasting The Future: 7 Analyst Projections For 4D Molecular Therapeutics
Via Benzinga
Eye Disease Focused 4D Molecular Therapeutics Lays Out 52-Week Results From Wet AMD Study
4D Molecular Therapeutics reported 52-week Phase 2b data for 4D-150 in wet AMD, showing sustained visual acuity improvements. 
Via Benzinga
A Glimpse Into The Expert Outlook On 4D Molecular Therapeutics Through 9 Analysts
Via Benzinga
A Glimpse Into The Expert Outlook On 4D Molecular Therapeutics Through 6 Analysts
Via Benzinga
What 5 Analyst Ratings Have To Say About 4D Molecular Therapeutics
Via Benzinga
Amazon To Rally Around 21%? Here Are 10 Top Analyst Forecasts For Wednesday
Via Benzinga
Analyst Expectations For 4D Molecular Therapeutics's Future
Via Benzinga
The Latest Analyst Ratings For 4D Molecular Therapeutics
Via Benzinga
Peeling Back The Layers: Exploring 4D Molecular Therapeutics Through Analyst Insights
Via Benzinga
4D Molecular Therapeutics Stock Falls After Follow-Up Data From Mid-Stage Study Of Vision Loss Drug Candidate
4D Molecular Therapeutics stock drops after the company shared interim data from the PRISM Phase 1/2 trial and details on its Phase 3 4FRONT study for wet AMD. The Phase 3 study comparing 4D-150 to... 
Via Benzinga
FDMT Stock Earnings: 4D Molecular Therapeutics Beats EPS for Q2 2024
FDMT stock results show that 4D Molecular Therapeutics beat analyst estimates for earnings per share the second quarter of 2024. 
Via InvestorPlace
Why Domino's Pizza Shares Are Trading Lower By Over 11%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Via Benzinga
Assessing 4D Molecular Therapeutics: Insights From 7 Financial Analysts
Via Benzinga
Analyst Expectations For 4D Molecular Therapeutics's Future
Via Benzinga
4D Molecular Therapeutics Stock: A Deep Dive Into Analyst Perspectives (5 Ratings)
Via Benzinga
What 4 Analyst Ratings Have To Say About 4D Molecular Therapeutics
Via Benzinga
4D Molecular Therapeutics Goes Neck To Neck With Rival, Shares New Phase 2 Data For Its Wet AMD Candidate
4D Molecular Therapeutics reports 24-week interim data from its PRISM Phase 2 trial, showing 77% of wet AMD patients injection-free with 4D-150. The trial highlights safety and efficacy in reducing... 
Via Benzinga
Why ASLAN Pharmaceuticals Shares Are Trading Lower By Over 38%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Via Benzinga
Goldman Sachs Optimistic About Regenxbio's Gene Therapy Pipeline, Sees Over 160% Upside
Goldman Sachs initiates coverage on RGNX, citing potential of gene therapy platform. 
Via Benzinga
Why Is 4D Molecular (FDMT) Stock Up 85% Today?
Investors in 4D Molecular Therapeutics and FDMT stock are seeing big gains today, as the stock surges 80% on positive trial results. 
Via InvestorPlace
Why G-III Apparel Shares Are Trading Lower By 13%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Via Benzinga
Why Is 4D Molecular Therapeutics Stock Trading Lower On Thursday? Genetic Disease-Focused Study Data Released
4D Molecular Therapeutics shares interim data from the 4D-710 Phase 1/2 AEROW clinical trial for cystic fibrosis lung disease. 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
FDMT Stock Earnings: 4D Molecular Therapeutics Beats EPS, Misses Revenue for Q1 2024
FDMT stock results show that 4D Molecular Therapeutics beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2024. 
Via InvestorPlace
To The Moon! A Look Inside An ETF Focused On Companies At The Cutting Edge Of Innovation
Via Benzinga
Topics ETFs
4D Molecular Therapeutics Outlines Pivotal Development Plans For Cystic Fibrosis, Rare Inherited Disease
4D Molecular Therapeutics' latest advancements in CF treatment. Get insights into their 4D-710 aerosolized genetic medicine for cystic fibrosis lung disease, including Phase 1/2 AEROW trial updates and... 
Via Benzinga
Why Is Blindness Focused-Adverum Biotechnologies Stock Trading Lower Today?
Adverum Biotechnologies' Ixo-vec gene therapy for wet AMD. Preliminary LUNA Phase 2 trial data show safety, efficacy, and significant treatment burden reduction. 
Via Benzinga
Why 4D Molecular Therapeutics (FDMT) Stock Is Diving
4D Molecular Therapeutics shares are trading lower by 12.7% Wednesday afternoon. The company announced pricing of an upsized underwritten public offering. 
Via Benzinga
4D Molecular Therapeutics' 4D-150 Phase 2 Data Met Investor Expectations, Analyst Boosts Forecast
4D Molecular Therapeutics' 4D-150 Phase 2 results for wet AMD treatment. BMO Capital optimistic, target price raised to $70. 
Via Benzinga
Crude Oil Moves Higher; Caterpillar Posts Upbeat Earnings
U.S. stocks traded lower toward the end of trading, with the Dow Jones index falling around 200 points on Monday. The Dow traded down 0.53% to 38,450.28 while the NASDAQ fell 0.11% to 15,612.52. The... 
Via Benzinga
Topics Stocks
Exposures Fossil Fuels US Equities
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.